nach oben

Drugs

Erschienen in:

01.07.2021 | Correction

Correction to: Fuzuloparib: First Approval

verfasst von: Arnold Lee

Erschienen in: Drugs | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Excerpt

Since publication online on 12 June 2021 of this AdisInsight Report on Fuzuloparib (AiRuiYi^®, 艾瑞颐; formerly fluzoparib), the agent was approved in China for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy on 22nd June 2021 [1]. …

NMPA approval website https://mp.weixin.qq.com/s/uJ0hgF_72eAzNLNUGfSuPQ. Accessed 2 July 2021.

Titel: Correction to: Fuzuloparib: First Approval
verfasst von: Arnold Lee
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 10/2021
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-021-01570-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Correction to: Fuzuloparib: First Approval

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Dostarlimab: First Approval

Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments

Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting

Loncastuximab Tesirine: First Approval

Current Status of Clinical Trials on Tau Immunotherapies

Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain